Insys Therapeutics Inc. (NASDAQ:INSY), a developer of opioid pain therapeutics that also has some cannabinoid product candidates in its pipeline, today announced the appointment of Andrew G. Long as the company's new Chief Financial Officer, effective August 7th.
Now Read: Insys Adds Four Pharma Industry Veterans To Leadership Team
Andrew G. Long has more than thirty years of experience in the finance departments of life sciences, biotechnology, pharmaceutical and industrial companies. Most recently, Mr. Long worked as a Senior Vice President of Global Finance at Patheon NV (NYSE:PTHN). While at Patheon, Long oversaw a number of initiatives leading up to Patheon’s IPO on the NYSE in 2016.
Prior to his role at Patheon, Mr. Long worked at Thermo Fisher Scientific (NYSE:TMO), Cambrex Corporation (NYSE:CBM) and Abbott Laboratories (NYSE:ABT).
If Abbott Laboratories sounds familiar to you, then it probably is, AbbVie Inc. (NYSE:ABBV) was spun out of Abbott Labs in 2013. AbbVie Inc. markets marketed a drug called Marinol. Marinol is a dronabinol capsule that is chemically identical to tetrahydrocannabinol, a.k.a. THC.
Now Read: Is AbbVie (NYSE:ABBV) a Marijuana Stock?
Saeed Motahari, President and Chief Executive Officer of Insys had this to say about the company's new hire:
“Andrew is a results-oriented, progressive leader with extensive global financial experience. His breadth of experience and proven record of building organizations and developing talent will complement the strengths of our senior management team. We look forward to his leadership and guidance as we focus on growing our business and developing our pipeline candidates”
He also thanked the company's previous CFO, Darryl Baker:
“I would like to thank Darryl Baker, who has served as our CFO since the Company’s IPO in 2013, for his commitment and many contributions to Insys.”
Now Read: 8 Marijuana Stocks Trading on the Nasdaq Exchange
For more information on Insys Therapeutics be sure to check out the company's profile in our global marijuana stock database. Remember, shares of Insys can be traded commission free using the Robinhood app.
Subscribe to one or more of our free e-mail newsletters so you never miss an important cannabis stock update. Also, don't forget to connect with The Daily Marijuana Observer on social media via Facebook, Twitter, StockTwits, and Instagram.
Investing in nanocap, microcap, and small cap stocks is highly speculative. The publishers of DailyMarijuanaObserver.com are not registered as Investment Advisors or Broker-Dealers in any jurisdiction whatsoever. The information contained on DailyMarijuanaObserver.com (“this site”) has been prepared solely for informational purposes. Nothing on the site is an offer or solicitation to buy or sell securities. Investors should seek financial advice regarding the appropriateness of investing in any securities mentioned from their financial advisor.